Lower GI 2017

Polish II – Trial (randomized phase III) High-risk criteria: fixed T3 or T4 („nonresectable“)

Wk 12

T M E

RT 50.4 Gy + Bolus 5-FU/LV 1.+ 5. week 50 mg/m 2 Oxaliplatin once weekly

R

Wk 12

T M E

5 x 5 Gy

FOLFOX 4 3#, q14

Primary endpoint: R0 resection rate (75% > 85%), 540 pts. required